Sexualhormone

Zusammenfassung

Sexualhormone werden zur Behandlung von Störungen der Sexualfunktion bei Mann und Frau eingesetzt. Sie dienen in erster Linie zur Substitution einer ungenügenden körpereigenen Hormonproduktion, aber auch zur Hemmung der Hormonproduktion durch Änderung der zentralen Regulationsvorgänge im Zwischenhirn und der Hypophyse.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American College of Obstetricians and Gynecologists (2013): Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121: 887–890Google Scholar
  2. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010): Adverse events associated with testosterone administration. N Engl J Med 363: 109–122Google Scholar
  3. Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, Marci R (2014): Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 8: 285–292Google Scholar
  4. Bundesminister für Gesundheit (2015): Verordnung zur Änderung der Arzneimittelverschreibungsverordnung und der Apothekenbetriebsordnung vom 6. März 2015. Bundesgesetzblatt 2015, Teil I, Nr. 10, Seite 278, ausgegeben zu Bonn am 13. März 2015Google Scholar
  5. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007): Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845Google Scholar
  6. Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception. Cochrane Database Syst Rev. 2004; (3): CD001324Google Scholar
  7. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators (2010): Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684–1692Google Scholar
  8. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553Google Scholar
  9. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097Google Scholar
  10. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (2014): Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014 Mar 3;3:CD010813. doi:  10.1002/14651858.CD010813.pub2. Review
  11. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (Hrsg) (2009): Hormontherapie in der Peri- und Postmenopause (HT). Internet: http://www.awmf.org/leitlinien/detail/ll/015-062.html
  12. Dinger J, Assmann A, Möhner S, Minh TD (2010): Risk of venous thromboembolism and the use of dienogestand drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36: 123–129Google Scholar
  13. Editorial (2015): HRT for menopause: a NICE treatment? Lancet 386: 2030Google Scholar
  14. Ford O, Lethaby A, Roberts H, Mol BW (2012): Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012 Mar 14;3:CD003415Google Scholar
  15. Gronich N, Lavi I, Rennert G (2011): Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319–1325Google Scholar
  16. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045Google Scholar
  17. Hickey M, Banks E (2016): NICE guidelines on the menopause. BMJ Jan 18; 352: i191Google Scholar
  18. Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2013): Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137: 2117–2122Google Scholar
  19. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593Google Scholar
  20. Keaney JF, Solomon CG (2016): Postmenopausal hormone therapy and atherosclerosis – Time is of the essence. N Engl J Med 374: 1279–1280Google Scholar
  21. Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9Google Scholar
  22. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators (2011): Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305: 1305–1314Google Scholar
  23. Larivée N, Suissa S, Khosrow-Khavar F, Tagalakis V, Filion KB (2017): Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies. BJOG Mar 9.doi:  10.1111/1471-0528.14623. [Epub ahead of print]
  24. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011): Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 25;343:d6423Google Scholar
  25. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E (2013): Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344: e2990Google Scholar
  26. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006): A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13: 737–743Google Scholar
  27. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O‘Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013): Meno pausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women‘s Health Initiative randomized trials. JAMA 310: 1353–1368Google Scholar
  28. McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989): Progesterone cream for cyclic breast pain. Brit Med J 289: 931Google Scholar
  29. Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427Google Scholar
  30. Million Women Study Collaborators (2005): Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551Google Scholar
  31. Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16–23Google Scholar
  32. National Institute for Health and Care Excellence (2015): Menopause: diagnosis and management. NICE guideline published 12 November 2015 (NG 23). Internet: https://www.nice.org.uk/guidance/ng23
  33. Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620Google Scholar
  34. Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182Google Scholar
  35. Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546Google Scholar
  36. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434Google Scholar
  37. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88Google Scholar
  38. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ (2015): Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100: 3975–4011Google Scholar
  39. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588Google Scholar
  40. Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712Google Scholar
  41. Writing Group for the Women’s Health Initiative Investigators (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlledtrial. JAMA 288: 321–333Google Scholar
  42. Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M (2013): Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG 120: 801–811Google Scholar
  43. Yang LP, Plosker GL (2012): Nomegestrol acetate/estradiol: in oral contraception. Drugs 72: 1917–1928Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Gynäkologische Endokrinologie und FertilitätsstörungenUniversitäts-FrauenklinikHeidelbergDeutschland

Personalised recommendations